$12.53
-0.75-5.65%
Last update: Nov 9, 4:44 PM
NovoCure Ltd
NVCRNASDAQ
NovoCure (NVCR) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
NovoCure (NVCR) last issued guidance on October 29, 2026 for fiscal year 2026. The company guided revenue in the range of $736M - $743M for the period.
Compared to prior guidance, NovoCure raised its revenue forecast from a prior range of $710M - $725M.
NovoCure has issued 12 guidance updates between January 9, 2023 and October 29, 2026. During this period, the company raised its outlook 8 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.23 | $-0.33 | $-0.49 | $-0.41 |
| Actual | $-0.09 | $-0.13 | $-0.62 | $-0.22 |
| Surprise | +60.9% | +60.6% | -26.5% | +46.3% |
| Revenue | ||||
| Estimate | $182.4M | $172.6M | $167.8M | $173.2M |
| Actual | $193.4M | $183.6M | $174.1M | $174.3M |
| Surprise | +6.00% | +6.35% | +3.73% | +0.67% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.21 | $-0.19 | $-0.16 | $-0.11 |
| Revenue | ||||
| Consensus | $189.8M | $191.1M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $-0.09 | $-0.23 | 60.9 % |
| Q2 | Jul 23, 2026 | $-0.13 | $-0.33 | 60.6 % |
| Q1 | Apr 30, 2026 | $-0.62 | $-0.49 | -26.5 % |
| Q4 | Feb 26, 2026 | $-0.22 | $-0.41 | 46.3 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $193.40M | $182.45M | 6.00 % |
| Q2 | Jul 23, 2026 | $183.58M | $172.62M | 6.35 % |
| Q1 | Apr 30, 2026 | $174.06M | $167.80M | 3.73 % |
| Q4 | Feb 26, 2026 | $174.35M | $173.18M | 0.67 % |
